Tryptophan
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Tryptophan: From Dietary Amino Acid Supplement to Restless Legs Syndrome
One-Sentence Summary
Tryptophan is an essential amino acid and metabolic precursor of serotonin and melatonin; it has no SAHPRA-registered therapeutic indication and is not currently marketed in South Africa. The TxGNN model predicts it may be effective for Restless Legs Syndrome (RLS), but this direction is currently supported only by 0 registered clinical trials and 8 publications, most of which are older, indirect, or drug-induced-RLS reports rather than direct treatment evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | None on record — Tryptophan has no approved therapeutic indication in South Africa; it is used internationally as a nutritional/dietary amino acid supplement |
| Predicted New Indication | Restless Legs Syndrome |
| TxGNN Prediction Score | 99.72% |
| Evidence Level | L3 |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap). Based on known pharmacology, tryptophan is an essential amino acid that serves as the metabolic precursor of serotonin (5-HT) and, downstream, melatonin. It has no approved indication in South Africa but is used as a nutritional/dietary supplement, and mechanistically it may be relevant to conditions influenced by serotonergic tone.
Because tryptophan has no registered original indication, there is no direct disease-to-disease analogy to draw on. The rationale for RLS instead rests on a shared neurotransmitter system: serotonergic and dopaminergic pathways interact in the regulation of motor and sensory signaling, and periodic-limb-movement/RLS symptoms have long been studied in relation to both pathways.
However, this mechanistic link should be interpreted cautiously: the accepted standard-of-care mechanism for RLS is dopaminergic (dopamine agonists are first-line treatment), and RLS pathophysiology is more consistently linked to iron metabolism and dopaminergic dysfunction than to serotonin. The tryptophan–RLS hypothesis is a minority mechanistic view supported mainly by small, decades-old studies rather than the mainstream disease model.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 3953904 | 1986 | Small clinical trial | American Journal of Psychiatry | Direct early clinical study of L-tryptophan for treatment of restless legs syndrome |
| 3659737 | 1987 | Clinical study (comparative) | Sleep | Compared periodic leg movement responses to L-dopa, 5-hydroxytryptophan, and L-tryptophan |
| 1305630 | 1992 | Review | International Journal of Neuroscience | Reviews serotonin’s role in CNS motor and neuropsychiatric functions, including movement disorders |
| 33836477 | 2021 | Systematic review/meta-analysis | Sleep Medicine Reviews | RLS is common in chronic liver disease; proposes elevated tryptophan, histamine, and dopamine turnover as contributing factors |
| 36897462 | 2023 | Case report | Neurological Sciences | RLS reported in DNAJC12 deficiency, a metabolic disease affecting combined dopaminergic/serotoninergic neurotransmission |
| 32546134 | 2020 | Pharmacovigilance study | BMC Psychiatry | Assesses antidepressant-associated movement disorders (drug-induced signal, not tryptophan treatment evidence) |
| 1777530 | 1991 | Case report | Biological Psychiatry | Describes RLS induced by lithium (drug-induced RLS, not treatment evidence) |
| 2881477 | 1987 | Review | American Family Physician | General review of insomnia diagnosis and treatment; only tangentially related to RLS |
South Africa Market Information
Tryptophan currently holds no SAHPRA product registrations and is not marketed in South Africa (0 licenses on record).
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Historical Safety Signal: One indexed trial record (NCT00001918) references the 1989 L-tryptophan-associated Eosinophilia-Myalgia Syndrome (EMS) outbreak, in which contaminated manufacturing batches of L-tryptophan supplements caused a potentially fatal eosinophilic illness. The contamination was traced to impurities from a specific manufacturing process rather than tryptophan itself, but it remains an important historical consideration for any clinical use of tryptophan supplements and underscores the need for pharmaceutical-grade sourcing and quality control.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for tryptophan in RLS consists of a single small 1986 trial and otherwise indirect, drug-induced-RLS, or mechanistic literature, with no currently registered clinical trials. The proposed serotonergic mechanism is not the mainstream RLS mechanism (dopaminergic/iron pathways predominate), and neither product safety data nor a confirmed mechanism of action are currently available.
To proceed, the following is needed:
- TFDA/SAHPRA-sourced Professional Information (warnings and contraindications) — currently a Blocking data gap
- Confirmed mechanism of action data from DrugBank — currently a High-severity data gap
- Modern controlled trials directly testing tryptophan supplementation in RLS patients
- Clarification of SAHPRA registration pathway, since tryptophan is not currently marketed in South Africa
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.